{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["30(11)"],"submitter":["Agarwal N"],"funding":["Eli Lilly and Company (Lilly)","Eli Lilly and Company"],"pubmed_abstract":["<h4>Purpose</h4>Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors radically changed the treatment paradigm for breast cancer. Similar to estrogen receptor in breast cancer, androgen receptor signaling activates cyclin D-CDK4/6, driving proliferation and resistance to hormonal manipulation in prostate cancer. This study was designed to detect signals of clinical activity for abemaciclib in treatment-refractory metastatic castration-resistant prostate cancer (mCRPC).<h4>Patients and methods</h4>Eligible patients had progressive mCRPC, measurable disease, and previously received ≥1 novel hormonal agent(s) and 2 lines of taxane chemotherapy. Abemaciclib 200 mg twice daily was administered on a continuous dosing schedule. Primary endpoint was objective response rate (ORR) without concurrent b"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pagination":["2377-2383"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11145166"],"repository":["biostudies-literature"],"pubmed_title":["A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1."],"pmcid":["PMC11145166"],"pubmed_authors":["Agarwal N","Gravis G","Rey PM","Schweizer MT","Colomba E","Arranz Arija JA","Gonzalez M","Appiah AK","Alonso-Gordoa T","Flechon A","Nacerddine K","Oudard S","Haddad N","Johnston E","Castellano D","Gallardo E","Mourey L","Balar A","Piulats JM"],"additional_accession":[]},"is_claimable":false,"name":"A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Results from CYCLONE 1.","description":"<h4>Purpose</h4>Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors radically changed the treatment paradigm for breast cancer. Similar to estrogen receptor in breast cancer, androgen receptor signaling activates cyclin D-CDK4/6, driving proliferation and resistance to hormonal manipulation in prostate cancer. This study was designed to detect signals of clinical activity for abemaciclib in treatment-refractory metastatic castration-resistant prostate cancer (mCRPC).<h4>Patients and methods</h4>Eligible patients had progressive mCRPC, measurable disease, and previously received ≥1 novel hormonal agent(s) and 2 lines of taxane chemotherapy. Abemaciclib 200 mg twice daily was administered on a continuous dosing schedule. Primary endpoint was objective response rate (ORR) without concurrent b","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-06-03T04:21:34.025Z","creation":"2026-04-24T03:09:58.24Z"},"accession":"S-EPMC11145166","cross_references":{"pubmed":["38512117"],"doi":["10.1158/1078-0432.CCR-23-3436"]}}